GRAY Graybug Vision, Inc. Stock Quote

GRAY [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	5.44%	Shs Outstand	20.98M	Perf Week	12.79%
Market Cap	602.67M	Forward P/E	-	EPS next Y	-2.29	Insider Trans	0.00%	Shs Float	19.84M	Perf Month	21.61%
Income	-	PEG	-	EPS next Q	-0.41	Inst Own	85.50%	Short Float	1.47%	Perf Quarter	93.58%
Sales	-	P/S	-	EPS this Y	-34.90%	Inst Trans	4.86%	Short Ratio	2.42	Perf Half Y	-
Book/sh	4.32	P/B	7.13	EPS next Y	42.70%	ROA	-	Target Price	35.00	Perf Year	-
Cash/sh	4.85	P/C	6.34	EPS next 5Y	-	ROE	-	52W Range	12.50 - 37.88	Perf YTD	6.06%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-18.74%	Beta	-
Dividend %	-	Quick Ratio	12.30	Sales past 5Y	-	Gross Margin	-	52W Low	146.24%	ATR	2.83
Employees	24	Current Ratio	12.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	59.40	Volatility	10.15% 10.71%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.31	Prev Close	31.88
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	120.73K	Price	30.78
Recom	1.60	SMA20	10.05%	SMA50	19.26%	SMA200	41.47%	Volume	36,924	Change	-3.45%

Dec-22-20

Initiated

Cantor Fitzgerald

Overweight

$42

Oct-20-20

Initiated

Wedbush

Outperform

$41

Oct-20-20

Initiated

SVB Leerink

Outperform

$35

Oct-20-20

Initiated

Piper Sandler

Overweight

$27

Oct-20-20

Initiated

Oppenheimer

Outperform

$41

Oct-20-20

Initiated

Needham

Buy

$30

Jan-07-21 07:30AM	Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021 GlobeNewswire
Dec-25-20 02:06AM	Here's Why We're Not Too Worried About Graybug Vision's (NASDAQ:GRAY) Cash Burn Situation Simply Wall St.
Dec-10-20 04:50PM	Is Graybug Vision (GRAY) A Good Stock To Buy Now? Insider Monkey -8.62%
Nov-16-20 04:05PM	Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference GlobeNewswire
Nov-12-20 04:05PM	Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate Developments GlobeNewswire -10.38%
Oct-27-20 07:48PM	Needham: 3 Strong Value Stocks to Buy Now TipRanks
Oct-14-20 04:42AM	AffaMed Therapeutics Announces Merger with EverInsight Therapeutics and Appoints Dayao Zhao, M.D., Ph.D. as CEO GlobeNewswire
Oct-01-20 11:57AM	Biotech Pulmonx Shares Climb in Trading Debut Barrons.com +6.06%
Sep-25-20 02:31PM	PMV Pharma Soars 115% as Biotech IPOs Take Off Barrons.com
12:43PM	Graybug Vision's stock open up 19%, then pares some gains MarketWatch
08:00AM	Graybug Appoints Three New Members to its Board of Directors GlobeNewswire
Sep-24-20 08:12PM	Graybug Vision Announces Pricing of Upsized Initial Public Offering GlobeNewswire

Graybug Vision, Inc., a clinical stage biopharmaceutical company, develops medicines for the treatment of diseases of the retina and optic nerve. Its lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials for the treatment of wet age-related macular degeneration, as well as in Phase IIa clinical trial to treat diabetic macular edema. The company is also developing GB-103, a once-a-year formulation of GB-102, for the treatment of diabetic retinopathy; and GB-401, a depot formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma. The company was formerly known as Graybug LLC and changed its name to Graybug Vision, Inc. in 2016. Graybug Vision, Inc. was founded in 2011 and is based in Redwood City, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience